Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
15 mars 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing product candidates designed to treat...
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
14 mars 2024 16h05 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed...
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
11 mars 2024 20h16 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed...
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
11 mars 2024 16h05 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed...
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
06 mars 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the...
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
26 févr. 2024 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders,...
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
06 févr. 2024 08h47 HE
|
Cognition Therapeutics, Inc.
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that...
Cognition Therapeutics CEO Issues Letter to Shareholders
04 janv. 2024 07h30 HE
|
Cognition Therapeutics, Inc.
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from Phase 2 SHIMMER trial in mild-to-moderate dementia with Lewy...
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
16 nov. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode:...
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
15 nov. 2023 07h30 HE
|
Cognition Therapeutics, Inc.
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the...